Market Research Logo

Superbugs & Superdrugs USA

Superbugs & Superdrugs USA

Broadening horizons on the growing global threat of Antimicrobial resistance (AMR) for almost two decades at the sell-out Superbugs & Superdrugs conference in Europe, SMi is thrilled to announce the expansion of its antimicrobial portfolio of events across the Atlantic with the release of Superbugs & Superdrugs USA. This year’s show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.

With huge interest from leaders in the field including PAHO/WHO, BARDA, NIH, Pfizer, AstraZeneca, Janssen and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs & Superdrugs event to date.

The program will hone in on key topics such as public private partnerships, collaboration, R&D, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
9:10
Global action plan on antimicrobial resistance
Pilar Ramon-Pardo, Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO
9:50
NIAID and National Strategy for CARB
Rosemarie Aurigemma, Chief, Biodefense Drug Development Section, DMID, NIAID, NIH
10:30
Morning Coffee
11:00
BARDA’s end-to-end support of antibacterial product development
Christopher Houchens, Branch Chief, Antibacterials Program, BARDA
11:40
Enabling drug discovery and development to address the crisis of antimicrobial resistance
John Rex, Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca
12:20
Networking Lunch
13:30
POL7080 – Polyphor’s new class of macrocycle antibiotic
Daniel Obrecht, Chief Scientific Officer, Polyphor
14:10
Antimicrobial combination therapy: Use and disuse
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
14:50
Innovative approaches to treating gram-negative infections
Scott Coleman, Head of Nonclinical Development, Spero Therapeutics
15:30
Afternoon Tea
16:00
Microbial metagenomics-based antibiotic discovery
David Pompliano, Co-Founder and CSO, Lodo Therapeutics
16:40
Targeting mechanisms of resistance using protein resistance neutralizers
David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd.
17:20
Chairman’s Closing Remarks and Close of Day One
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
9:10
First to know and fast to market
Mahesh Kumar, Vice President, Global Biological Research and Development, Zoetis
9:50
Novel protein-based biologics for the treatment and prevention of serious bacterial infections
Anthony Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC
10:30
Morning Coffee
11:00
Progress towards developing vaccines for the prevention of Staphylococcus aureus infections
Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
11:40
The novel strategy to fight multidrug resistance by multiple drugs synergism, based on docking in drug design and TRIZ
Boris Farber, CEO, Noigel, LLC
12:20
Networking Lunch
13:30
What can be done in order to be successful?
Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
14:10
Addressing the evolving challenge of ß-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad spectrum activity against Class A, C and D enzymes
Alita Miller, Head of Bioscience, Entasis Therapeutics
14:50
Afternoon Tea
15:20
Novel beta-lactamase inhibitors to calm the carbapenemase storm
Olga Lomovskaya, Vice President, Biology, The Medicines Company
16:00
Collaborative development of novel drugs to prevent infection
Ian Hayter, Projects Director, Destiny Pharma Ltd
16:40
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report